Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension.
Publication/Presentation Date
3-16-2021
Abstract
Interferonopathies, interferon (IFN)-α/β therapy, and caveolin-1 (CAV1) loss-of-function have all been associated with pulmonary arterial hypertension (PAH). Here, CAV1-silenced primary human pulmonary artery endothelial cells (PAECs) were proliferative and hypermigratory, with reduced cytoskeletal stress fibers. Signal transducers and activators of transcription (STAT) and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) were both constitutively activated in these cells, resulting in a type I IFN-biased inflammatory signature.
Volume
118
Issue
11
ISSN
1091-6490
Published In/Presented At
Gairhe, S., Awad, K. S., Dougherty, E. J., Ferreyra, G. A., Wang, S., Yu, Z. X., Takeda, K., Demirkale, C. Y., Torabi-Parizi, P., Austin, E. D., Elinoff, J. M., & Danner, R. L. (2021). Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension. Proceedings of the National Academy of Sciences of the United States of America, 118(11), e2010206118. https://doi.org/10.1073/pnas.2010206118
Disciplines
Medicine and Health Sciences
PubMedID
33836561
Department(s)
Department of Medicine
Document Type
Article